Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies
he company posted total income during Q2 FY24 at Rs. 12.86 crore
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
This order is subject to initial advance payment as per the agreed terms of the contract
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
The company has predominantly built a portfolio into veterinary products
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The company also plans to register the similar range of products in the neighbouring countries.
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
